V8P Juice International LLC

WARNING LETTER V8P Juice International LLC MARCS-CMS 577723 — August 08, 2019 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Product: Tobacco Recipient: Recipient Name Alex De La Espriella Recipient Title Owner V8P Juice International LLC 1021 South Rogers Circle, Suite 14 Boca Raton , FL 33487-2857 United States Issuing Office: Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring , MD 20993 United States VIA UPS and Electronic Mail Reference #: ER1900024 AUG 8, 2019 Alex De La Espriella Owner V8P Juice International LLC 1021 South Rogers Circle, Suite 14 Boca Raton, FL  33487-2857 V8PJuice@gmail.com WARNING LETTER Dear Mr. De La Espriella: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records and determined that V8P Juice International LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquids products are manufactured and offered for sale or distribution to customers in the United States.  Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), as amended by the Family Smoking Prevention and Tobacco Control Act, these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA’s jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)). FDA has determined that your V8P Saltz Blonde Bombshell , V8P Saltz Mami Merengue , V8P Saltz Port Master , V8P Saltz Last Samurai , V8P Saltz Cowboy Killer , and V8P Saltz Caribbean Don e-liquids are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)) for not having a required FDA marketing authorization order in effect and/or misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a required notice or other information respecting the products was not provided. New Tobacco Products Without Required Marketing Authorization Are Adulterated and/or Misbranded FDA has determined that you manufacture, sell, and distribute to customers in the United States the following e-liquid products without a marketing authorization order: V8P Saltz Blonde Bombshell , V8P Saltz Mami Merengue , V8P Saltz Port Master , V8P Saltz Last Samurai , V8P Saltz Cowboy Killer , and V8P Saltz Caribbean Don. The FD&C Act generally requires premarket review for any “new tobacco product,” which means any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modification of a tobacco product where the modified product was commercially marketed in the United States after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)).  A marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) FDA issues an order fi n ding the product to be exempt f r o m the requ i rements o f substantial equivalence and you ma k e the re q uired sub m ission und e r sec t ion 905(j ) ( 1 )(A )(i i ) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)).  All deemed products that meet the definition of a “new tobacco product,” including e-liquids, are subject to the premarket requirements in sections 910 and 905 of the FD&C Act. FDA has determined that the following e-liquid products were not commercially marketed in the United States as of February 15, 2007: V8P Saltz Blonde Bombshell , V8P Saltz Mami Merengue , V8P Saltz Port Master , V8P Saltz Last Samurai , V8P Saltz Cowboy Killer , and V8P Saltz Caribbean Don. These products are required to have premarket review and do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act.  Therefore, they are adulterated under section 902(6)(A) of the FD&C Act.  In addition, they are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).  The introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)).  Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)). Conclusion and Requested Actions The violations discussed in this letter do not necessarily constitute an exhaustive list.  You should immediately correct the violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations.  Failure to ensure full compliance with the FD&C Act may result in FDA initiating further action without notice, including, but not limited to, civil money penalties, criminal prosecution, seizure, and/or injunction.  Please note that any adulterated and/or misbranded tobacco products offered for import into the United States are subject to detention and refusal of admission. Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and/or distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act.  If you do not believe that your products are in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.  You can find the FD&C Act through links on FDA’s homepage at http://www.fda.gov . Please note your reference number, ER1900024, in your response and direct your response to the following address: DEM-WL Response, Office of Compliance and Enforcement FDA Center for Tobacco Products c/o Document Control Center Building 71, Room G335 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov . Sincerely, /S/ Ann Simoneau, J.D. Director Office of Compliance and Enforcement Center for Tobacco Products Content current as of: 08/08/2019 Regulated Product(s) Tobacco